BCLI
Brainstorm Cell Therapeutics Inc.
Biotechnology
Market Cap$7M
5Y Perf.-99.4%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
BCLI vs AGEN vs NKTR vs FATE
Revenue, margins, valuation, and 5-year total return — side by side.
AGEN
Agenus Inc.
Biotechnology
Market Cap$132M
5Y Perf.-95.0%
NKTR
Nektar Therapeutics
Biotechnology
Market Cap$1.69B
5Y Perf.-74.4%
FATE
Fate Therapeutics, Inc.
Biotechnology
Market Cap$280M
5Y Perf.-92.5%
BCLI vs AGEN vs NKTR vs FATE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BCLI | AGEN | NKTR | FATE |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $7M | $132M | $1.69B | $280M |
| Revenue (TTM) | $849K | $114M | $55M | $7M |
| Net Income (TTM) | $-11M | $115K | $-164M | $-136M |
| Gross Margin | 61.5% | 35.7% | 99.6% | — |
| Operating Margin | -14.0% | -17.7% | -237.9% | -22.2% |
| Forward P/E | 0.3x | 1.8x | — | — |
| Total Debt | $720K | $10M | $149M | $78M |
| Cash & Equiv. | $187K | $3M | $15M | $47M |
BCLI vs AGEN vs NKTR vs FATE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BCLI
AGEN
NKTR
FATE
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Brainstorm Cell The… (BCLI) | 100 | 0.6 | -99.4% |
| Agenus Inc. (AGEN) | 100 | 5.0 | -95.0% |
| Nektar Therapeutics (NKTR) | 100 | 25.6 | -74.4% |
| Fate Therapeutics, … (FATE) | 100 | 7.5 | -92.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BCLI vs AGEN vs NKTR vs FATE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: BCLI leads in 3 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. Agenus Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. NKTR also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
BCLI
Brainstorm Cell Therapeutics Inc.
The Income Pick
BCLI carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.12
- Rev growth 147.5%, EPS growth 148.9%
- 147.5% revenue growth vs FATE's -51.2%
- Better valuation composite
Best for: income & stability and growth exposure
AGEN
Agenus Inc.
The Quality Compounder
AGEN is the #2 pick in this set and the best alternative if quality and efficiency is your priority.
- 0.1% margin vs FATE's -20.5%
- 0.1% ROA vs BCLI's -446.1%
Best for: quality and efficiency
NKTR
Nektar Therapeutics
The Long-Run Compounder
NKTR is the clearest fit if your priority is long-term compounding and defensive.
- -59.1% 10Y total return vs FATE's 40.5%
- Beta 1.85, current ratio 4.97x
- +8.2% vs BCLI's -42.7%
Best for: long-term compounding and defensive
FATE
Fate Therapeutics, Inc.
The Defensive Pick
FATE is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 2.17, Low D/E 37.6%, current ratio 5.79x
Best for: sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | BCLI | 147.5% revenue growth vs FATE's -51.2% |
| Value | BCLI | Better valuation composite |
| Quality / Margins | AGEN | 0.1% margin vs FATE's -20.5% |
| Stability / Safety | BCLI | Beta 1.12 vs AGEN's 2.72 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | NKTR | +8.2% vs BCLI's -42.7% |
| Efficiency (ROA) | AGEN | 0.1% ROA vs BCLI's -446.1% |
BCLI vs AGEN vs NKTR vs FATE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
FY 2025
FY 2023
BCLI vs AGEN vs NKTR vs FATE — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLAGENLAGGINGBCLI
Who Leads Where
AGEN leads in 2 of 6 categories
FATE leads 1 • NKTR leads 1 • BCLI leads 0 • 1 tied
Explore the data ↓BCLIBrainstorm Cell Thera…
0leads
FATEFate Therapeutics, In…
1leads
NKTRNektar Therapeutics
1leads
AGENAgenus Inc.
2leads
6 Total Categories
CATEGORYLEADERvs NKTRvs FATEMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
AGEN5/6
Valuation MetricsMultiples, price ratios, and targets
AGEN2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
FATE4/9
Total Returns1Y, 3Y, 5Y total returns with dividends
NKTR4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
AGEN leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
AGEN is the larger business by revenue, generating $114M annually — 134.5x BCLI's $849,000. AGEN is the more profitable business, keeping 0.1% of every revenue dollar as net income compared to FATE's -20.5%. On growth, AGEN holds the edge at +27.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | BCLIBrainstorm Cell T… | AGENAgenus Inc. | NKTRNektar Therapeuti… | FATEFate Therapeutics… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $849,000 | $114M | $55M | $7M |
| EBITDAEarnings before interest/tax | -$12M | -$10M | -$130M | -$148M |
| Net IncomeAfter-tax profit | -$11M | $115,000 | -$164M | -$136M |
| Free Cash FlowCash after capex | -$9M | -$159M | -$209M | -$88M |
| Gross MarginGross profit ÷ Revenue | +61.5% | +35.7% | +99.6% | — |
| Operating MarginEBIT ÷ Revenue | -14.0% | -17.7% | -2.4% | -22.2% |
| Net MarginNet income ÷ Revenue | -13.5% | +0.1% | -3.0% | -20.5% |
| FCF MarginFCF ÷ Revenue | -11.2% | -139.1% | -3.8% | -13.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +27.5% | -25.3% | -26.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +37.0% | +85.3% | -4.5% | +38.6% |
AGEN leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
AGEN leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | BCLIBrainstorm Cell T… | AGENAgenus Inc. | NKTRNektar Therapeuti… | FATEFate Therapeutics… |
|---|---|---|---|---|
| Market CapShares × price | $7M | $132M | $1.7B | $280M |
| Enterprise ValueMkt cap + debt − cash | $8M | $140M | $1.8B | $312M |
| Trailing P/EPrice ÷ TTM EPS | 0.32x | -1102.94x | -8.57x | -2.11x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 1.79x | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | 8.27x | 1.16x | 30.64x | 42.18x |
| Price / BookPrice ÷ Book value/share | — | — | 15.66x | 1.39x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — |
AGEN leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
FATE leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
FATE delivers a -65.8% return on equity — every $100 of shareholder capital generates $-66 in annual profit, vs $-4 for NKTR. FATE carries lower financial leverage with a 0.38x debt-to-equity ratio, signaling a more conservative balance sheet compared to NKTR's 1.66x. On the Piotroski fundamental quality scale (0–9), AGEN scores 6/9 vs FATE's 2/9, reflecting solid financial health.
| Metric | BCLIBrainstorm Cell T… | AGENAgenus Inc. | NKTRNektar Therapeuti… | FATEFate Therapeutics… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | — | — | -4.0% | -65.8% |
| ROA (TTM)Return on assets | -4.5% | +0.1% | -62.8% | -42.7% |
| ROICReturn on invested capital | — | — | -57.2% | -36.5% |
| ROCEReturn on capital employed | — | — | -55.7% | -43.1% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 6 | 2 | 2 |
| Debt / EquityFinancial leverage | — | — | 1.66x | 0.38x |
| Net DebtTotal debt minus cash | $533,000 | $7M | $134M | $31M |
| Cash & Equiv.Liquid assets | $187,000 | $3M | $15M | $47M |
| Total DebtShort + long-term debt | $720,000 | $10M | $149M | $78M |
| Interest CoverageEBIT ÷ Interest expense | -26.44x | 1.11x | -4.74x | — |
FATE leads this category, winning 4 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
NKTR leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NKTR five years ago would be worth $2,765 today (with dividends reinvested), compared to $146 for BCLI. Over the past 12 months, NKTR leads with a +818.2% total return vs BCLI's -42.7%. The 3-year compound annual growth rate (CAGR) favors NKTR at 93.3% vs BCLI's -74.9% — a key indicator of consistent wealth creation.
| Metric | BCLIBrainstorm Cell T… | AGENAgenus Inc. | NKTRNektar Therapeuti… | FATEFate Therapeutics… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +13.7% | +16.1% | +92.0% | +145.5% |
| 1-Year ReturnPast 12 months | -42.7% | +27.1% | +818.2% | +143.0% |
| 3-Year ReturnCumulative with dividends | -98.4% | -88.2% | +621.8% | -55.4% |
| 5-Year ReturnCumulative with dividends | -98.5% | -93.9% | -72.3% | -96.8% |
| 10-Year ReturnCumulative with dividends | -97.8% | -94.3% | -59.1% | +40.5% |
| CAGR (3Y)Annualised 3-year return | -74.9% | -51.0% | +93.3% | -23.6% |
NKTR leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — BCLI and FATE each lead in 1 of 2 comparable metrics.
Risk & Volatility
BCLI is the less volatile stock with a 1.12 beta — it tends to amplify market swings less than AGEN's 2.72 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FATE currently trades 98.6% from its 52-week high vs BCLI's 36.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BCLIBrainstorm Cell T… | AGENAgenus Inc. | NKTRNektar Therapeuti… | FATEFate Therapeutics… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.12x | 2.72x | 1.85x | 2.17x |
| 52-Week HighHighest price in past year | $1.92 | $7.34 | $109.00 | $2.46 |
| 52-Week LowLowest price in past year | $0.46 | $2.71 | $7.99 | $0.91 |
| % of 52W HighCurrent price vs 52-week peak | +36.1% | +51.1% | +76.5% | +98.6% |
| RSI (14)Momentum oscillator 0–100 | 39.3 | 48.8 | 53.4 | 81.0 |
| Avg Volume (50D)Average daily shares traded | 9K | 814K | 991K | 1.9M |
Evenly matched — BCLI and FATE each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: AGEN as "Buy", NKTR as "Buy", FATE as "Buy". Consensus price targets imply 1525.5% upside for FATE (target: $40) vs 59.3% for NKTR (target: $133).
| Metric | BCLIBrainstorm Cell T… | AGENAgenus Inc. | NKTRNektar Therapeuti… | FATEFate Therapeutics… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $7.33 | $132.83 | $39.50 |
| # AnalystsCovering analysts | — | 11 | 33 | 31 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 1 | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.1% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
AGEN leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). FATE leads in 1 (Profitability & Efficiency). 1 tied.
Best OverallAgenus Inc. (AGEN)Leads 2 of 6 categories
Loading custom metrics...
BCLI vs AGEN vs NKTR vs FATE: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is BCLI or AGEN or NKTR or FATE a better buy right now?
For growth investors, Agenus Inc.
(AGEN) is the stronger pick with 10. 4% revenue growth year-over-year, versus -51. 2% for Fate Therapeutics, Inc. (FATE). Brainstorm Cell Therapeutics Inc. (BCLI) offers the better valuation at 0. 3x trailing P/E, making it the more compelling value choice. Analysts rate Agenus Inc. (AGEN) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BCLI or AGEN or NKTR or FATE?
Over the past 5 years, Nektar Therapeutics (NKTR) delivered a total return of -72.
3%, compared to -98. 5% for Brainstorm Cell Therapeutics Inc. (BCLI). Over 10 years, the gap is even starker: FATE returned +40. 5% versus BCLI's -97. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BCLI or AGEN or NKTR or FATE?
By beta (market sensitivity over 5 years), Brainstorm Cell Therapeutics Inc.
(BCLI) is the lower-risk stock at 1. 12β versus Agenus Inc. 's 2. 72β — meaning AGEN is approximately 142% more volatile than BCLI relative to the S&P 500. On balance sheet safety, Fate Therapeutics, Inc. (FATE) carries a lower debt/equity ratio of 38% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.
04Which is growing faster — BCLI or AGEN or NKTR or FATE?
By revenue growth (latest reported year), Agenus Inc.
(AGEN) is pulling ahead at 10. 4% versus -51. 2% for Fate Therapeutics, Inc. (FATE). On earnings-per-share growth, the picture is similar: Brainstorm Cell Therapeutics Inc. grew EPS 148. 9% year-over-year, compared to -12. 1% for Nektar Therapeutics. Over a 3-year CAGR, AGEN leads at 5. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — BCLI or AGEN or NKTR or FATE?
Brainstorm Cell Therapeutics Inc.
(BCLI) is the more profitable company, earning 1369% net margin versus -20. 5% for Fate Therapeutics, Inc. — meaning it keeps 1369% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AGEN leads at -18. 0% versus -22. 2% for FATE. At the gross margin level — before operating expenses — BCLI leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is BCLI or AGEN or NKTR or FATE more undervalued right now?
Analyst consensus price targets imply the most upside for FATE: 1525.
5% to $39. 50.
07Which pays a better dividend — BCLI or AGEN or NKTR or FATE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is BCLI or AGEN or NKTR or FATE better for a retirement portfolio?
For long-horizon retirement investors, Brainstorm Cell Therapeutics Inc.
(BCLI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 12)). Agenus Inc. (AGEN) carries a higher beta of 2. 72 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BCLI: -97. 8%, AGEN: -94. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between BCLI and AGEN and NKTR and FATE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: BCLI is a small-cap deep-value stock; AGEN is a small-cap quality compounder stock; NKTR is a small-cap quality compounder stock; FATE is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.